QQ客服 官方微博 反馈留言

	Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
	Hao Xing; Xing Wen; Yuan Jiajia; Wang Yingshao; Bai Jiaojiao; Bai Jie; Zhou Yuan
	2019
关键词	Combination therapy HDAC JAK2V617F Myeloproliferative neoplasms Ruxolitinib Vorinostat
ISSN号	1573-0646
DOI	10.1007/s10637-019-00794-4
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6337869
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Hao Xing,Xing Wen,Yuan Jiajia,et al. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms[J],2019.
APA	Hao Xing.,Xing Wen.,Yuan Jiajia.,Wang Yingshao.,Bai Jiaojiao.,...&Zhou Yuan.(2019).Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms..
MLA	Hao Xing,et al."Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms".(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。